Whilst this difference was not statistically significant the fact that temozolomide can be effective in patients with nonmethylated MGMT status is intriguing and raises the question of should we be treating all patients of GBM with temozolomide irrespective of their MGMT methylation status. The gene discussed is MGMT; the disease is glioblastoma.